{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:28:43Z","timestamp":1789820923988,"version":"4.0.1"},"reference-count":43,"publisher":"Wiley","issue":"s2","license":[{"start":{"date-parts":[[2008,2,28]],"date-time":"2008-02-28T00:00:00Z","timestamp":1204156800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2008,3]]},"abstract":"<jats:p>Prostate cancer predominantly affects older men, with a median age at diagnosis of 68 years. Due to the increased life expectancy, management of prostate cancer in senior adults (aged &gt;70 years) represents a major public health problem. This patient population may not receive optimal therapy for their disease, if decisions are made based on their chronological age alone. More so than age alone, health status is a major factor affecting individual life expectancy. Comorbidity is the key predictor of health status and should weigh more heavily on the treatment decision than age alone. Other important parameters to consider in senior adults are the degree of dependence in activities of daily living, the nutritional status and the presence or not of a geriatric syndrome. Although clinical trials are rarely designed specifically for senior adults, evidence suggests that healthy senior adults have similar treatment outcomes to their younger counterparts.<\/jats:p>\n                  <jats:p>\n                    The urological approach in senior adults with advanced prostate cancer should be fundamentally the same as in younger patients. In hormone\u2010sensitive metastatic prostate cancer, androgen deprivation represents the first\u2010line treatment. In senior adults, care should be given to the increased risk of metabolic syndrome, cardiovascular mortality and bone fracture. In hormone\u2010refractory metastatic prostate cancer, chemotherapy with docetaxel (75\u2003mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    every 3 weeks) plus low\u2010dose prednisone is the standard and shows the same efficacy in healthy senior adults as in younger patients. The tolerance of docetaxel (3\u2010weekly schedule) has not been specifically studied in vulnerable and frail senior adults. The place of weekly docetaxel in this setting should be further evaluated. Palliative treatments (palliative surgery, radiopharmaceutics, radiotherapy, medical treatments for pain and symptoms, pharmacological palliative therapies) should also be integrated in the global management of these patients.\n                  <\/jats:p>\n                  <jats:p>In conclusion, treatment decisions in senior adults should be adapted to health status. Healthy senior adults should be treated the same as younger patients. The development of guidelines for the management of localized and advanced prostate cancer in senior adults is underway.<\/jats:p>","DOI":"10.1111\/j.1464-410x.2007.07486.x","type":"journal-article","created":{"date-parts":[[2008,2,28]],"date-time":"2008-02-28T05:37:56Z","timestamp":1204177076000},"page":"23-29","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Management of metastatic prostate cancer: the crucial role of geriatric assessment"],"prefix":"10.1111","volume":"101","author":[{"given":"Jean\u2010Pierre","family":"Droz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieska","family":"Chaladaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,2,28]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl498"},{"key":"e_1_2_8_3_2","unstructured":"RiesLA MelbertD KrapchoMet\u2003al.eds.SEER Cancer Statistics Review 1975\u20132004 National Cancer Institute Bethesda MD USA based on November 2006 SEER data submission. Available at:http:\/\/seer.cancer.gov\/csr\/1975_2004\/. Accessed January 2008"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.091"},{"key":"e_1_2_8_5_2","unstructured":"National Comprehensive Cancer Network.NCCN oncology guidelines 2007: prostate cancer. Available at:http:\/\/www.nccn.org. Accessed January 2008"},{"key":"e_1_2_8_6_2","unstructured":"HeidenreichA AusG AbbouCCet\u2003al.EAU guidelines on prostate cancer 2007 update. Available at:http:\/\/www.uroweb.org\/fileadmin\/user_upload\/Guidelines\/07_Prostate_Cancer_2007.pdf. Accessed January 2008"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm028"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02163-2"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2006.06.006"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2003.10.063"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.2497"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.3369"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)65165-6"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041943"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.07163.x"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005131-200501000-00006"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1997.tb126646.x"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199810083391504"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4008"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041318"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2006.06526.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.9-5-538"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.01.104"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.3816\/CGC.2003.n.025"},{"key":"e_1_2_8_26_2","first-page":"609","article-title":"Scales to measure competence in everyday activities","volume":"24","author":"Lawton MP","year":"1988","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(92)90005-N"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.6.1756"},{"key":"e_1_2_8_29_2","doi-asserted-by":"crossref","unstructured":"BertholdD PondG De WittRet\u2003al.Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. ASCO prostate 2007 (poster)","DOI":"10.1093\/annonc\/mdn288"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh429"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.1.44"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2000.00673.x"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820901)50:5<893::AID-CNCR2820500515>3.0.CO;2-Y"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-8140(94)90411-1"},{"key":"e_1_2_8_35_2","first-page":"1839","article-title":"Samarium\u2010153\u2010EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I\/II trial","volume":"34","author":"Collins C","year":"1993","journal-title":"J Nucl Med"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010715)92:2<303::AID-CNCR1323>3.0.CO;2-F"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900201)65:3<586::AID-CNCR2820650333>3.0.CO;2-P"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1993.tb15926.x"},{"key":"e_1_2_8_39_2","first-page":"347","article-title":"Coagulopathy in prostate cancer","volume":"61","author":"De La Fouchardiere C","year":"2003","journal-title":"Neth J Med"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.21.2750"},{"key":"e_1_2_8_41_2","article-title":"United States life tables, 2003","volume":"54","author":"Arias E","year":"2003","journal-title":"Natl Vit Stat Rep"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)00018-2"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.00588.x"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2007.07486.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2007.07486.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:49:54Z","timestamp":1761745794000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2007.07486.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,28]]},"references-count":43,"journal-issue":{"issue":"s2","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["10.1111\/j.1464-410X.2007.07486.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2007.07486.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,28]]},"assertion":[{"value":"2008-02-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}